Antonioli, L
Most patients tolerate Cyanocobalamin well
Eli Lilly releases clinical data on the triple agonist Retatrutide, with fierce competition in the GLP-1R agonist market!) Orforglipron (OWL833, LY3502970) is a small molecule agonist targeting GLP-1R, originally developed by Chugai
Patients with a history (or family history) of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not take Ozempic or Trulicity
5a), a pro-drug that combines sulphapyridine (an antibiotic) and 5-aminosalicylic (an anti-inflammatory agent) linked by an azo bridge, has huge therapeutic potential, but is, unfortunately, labile under physiological conditions (70% degradation by colonic bacteria via azo cleavage
KSA: Demand for GLP-1 companion products in Saudi Arabia is projected to grow at around an 11.6% CAGR through 2036, supported by improving healthcare and food manufacturing infrastructure, and increasing adoption of convenient formats such as high-protein bars, hydration solutions, and fiber-based digestive health products